Clinical Trials and Research Studies

At NYU Langone Health, our doctors and researchers perform clinical trials and research studies with the aim of translating findings into new, more effective treatments.

Recently Added/Updated Trials

  • M20-638: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL TRIAL OF EPCORITAMAB IN COMBINATION WITH RITUXIMAB AND LENALIDOMIDE (R2) COMPARED TO RITUXIMAB AND LENALIDOMIDE (R2) ALONE IN SUBJECTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

    This is a trial testing a new medicine called epcoritamab, when used with other medicines called rituximab and lenalidomide (together called "R2"), to see if ...

    View Details

  • An Open-label Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Antitumor Activity of TAK-500 a Novel Stimulator of Interferon Genes Agonist as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors

    TAK-500-1001 is a phase 1/2, open-label, dose escalation and expansion study designed to determine the safety, tolerability, antitumor activity, pharmacokinetics (PK), pharmacodynamics, and preliminary ...

    View Details

  • A Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Anti-tumor Activity of TNG908 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors

    TNG908 is a potent and selective oral small molecule inhibitor of PRMT5 that binds cooperatively with MTA to inhibit PRMT5 function. Elevated levels of MTA ...

    View Details

  • A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer

    This study aims to see how well a new drug, EIK1001, works when given with pembrolizumab and certain chemotherapies in patients with Stage 4 lung ...

    View Details

  • AN OPEN-LABEL MULTICENTER PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AB-2100 IN PATIENTS WITH RECURRENT ADVANCED OR METASTATIC CLEAR-CELL RENAL CELL CARCINOMA (CCRCC)

    This is an open-label, multicenter Phase 1/2 study evaluating the safety, efficacy, cellular kinetics, immunogenicity, and pharmacodynamics of AB-2100 in adult subjects with recurrent ...

    View Details

  • A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)

    A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with ...

    View Details

  • A single-center observational longitudinal study to monitor skeletal muscle aging with quantitative MRI

    The muscles in your legs and shoulders change as you get older and they become weaker. The purpose of this study is to investigate new ...

    View Details

  • A SINGLE-CENTER OBSERVATIONAL STUDY OF CLINICAL OUTCOMES FOLLOWING TREATMENT OF LEIOMYOMA WITH COMBINATION THERAPY UTILIZING GNRH ANALOGS AND TRANSCERVICAL FIBROID ABLATION

    This is a prospective cohort study of patients who will receive TFA following medical therapy for fibroid care between 1/2023 and 1/2024 at ...

    View Details